Predicting Response to PD-1 Inhibitor Therapy in Melanoma Patients
Author Information
Author(s): Hegyi Barbara, Csikó Kristóf György, Balatoni Tímea, Fröhlich Georgina, Bőcs Katalin, Tóth Erika, Mohos Anita, Neumark Anna Rebeka, Menyhárt Csenge Dorottya, Ferrone Soldano, Ladányi Andrea, Camps Jordi, Fort Gallifa Isabel, Gabaldó Barrios Xavier
Primary Institution: National Institute of Oncology, Budapest, Hungary
Hypothesis
Can tumor-infiltrating immune cells and HLA expression predict the response to PD-1 inhibitor therapy in stage IV melanoma patients?
Conclusion
The study found that higher HLA class II expression and greater immune cell infiltration are associated with better responses to PD-1 inhibitor therapy in melanoma patients.
Supporting Evidence
- Among responders, a higher proportion showed HLA-II expression compared to non-responders.
- A combined score of HLA-I and II expression effectively predicted treatment response.
- Intratumoral immune cell density was higher in responders for most immune cell types.
- Progression-free survival was associated with HLA-II expression and immune cell density.
Takeaway
Researchers looked at samples from melanoma patients to see if certain immune cells and proteins could help predict how well they would respond to a specific cancer treatment.
Methodology
The study analyzed pretreatment surgical samples from 40 stage IV melanoma patients using immunohistochemistry to assess HLA expression and immune cell infiltration.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the selection criteria used.
Limitations
The study is retrospective and limited to pretreatment samples, which may not account for changes in the tumor microenvironment during therapy.
Participant Demographics
The cohort consisted of 40 stage IV melanoma patients, with a median age of 62 years.
Statistical Information
P-Value
p = 0.0019
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website